DAFTAR PUSTAKA

1. Ciaccio M, Agnello L. Biochemical biomarkers alterations in Coronavirus Disease 2019 (COVID-19). Diagnosis. 2020;0(0).

2. Huang I, Pranata R, Lim MA, et al. C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis. Ther Adv Respir Dis. 2020;14:1–14.

3. Ponti G, Maccaferri M, Ruini C, et al. Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci. 2020;0(0):1–11.

4. Manjili RH, Zarei M, Habibi M, et al. COVID-19 as an Acute Inflammatory Disease. J Immunol. 2020;205(1):12–9.

5. Edeas M, Saleh J, Peyssonnaux C. Iron: Innocent bystander or vicious culprit in COVID-19 pathogenesis? Int J Infect Dis. 2020;97:303–5.

6. Lin Z, Long F, Yang Y, et al. Serum ferritin as an independent risk factor for severity in COVID-19 patients. J Infect. 2020;81(4):647–79.

7. Čepelak I, Dodig S, Vučenik I. Hyperferritinemia and COVID-19? Rad Hrvat Akad Znan i Umjet Med Znan. 2020;544(52–53):18–25.

8. Rosário C, Zandman-Goddard G, Meyron-Holtz EG, et al. The Hyperferritinemic Syndrome: Macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med. 2013;11(1).

9.   Shekhanawar M, Sarala H, Riyaz S. Section : Biochemistry Serum Ferritin and C - Reactive Protein as Prognostic Factors in Patients with Novel Coronavirus 2019. Asian J Med Res. 2021;10(2):9–17.

10.   Siripanthong B, Cantab BA, Nazarian S, et al. Recognizing COVID-19 – related myocarditis : The possible pathophysiology and proposed guideline for diagnosis and management. Hear Rhythm. 2020;17(9):1463–71.

11.   Madjid M, Safavi-Naeini P, Solomon SD, et al. Potential Effects of Coronaviruses on the Cardiovascular System: A Review. JAMA Cardiol. 2020;10:1–10.

12.   Clerkin KJ, Fried JA, Raikhelkar J, et al. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease. Circulation. 2020;2019:1648–55.

13.   World Health Organization. Global Surveillance for COVID-19 disease caused by human infection with novel coronavirus (COVID-19). 2020;(January):2019–20.

14.   World Health Organization. Weekly Epidemiological Update on COVID-19. 2020;(October).

15.   Kesehatan K. Pedoman Pencegahan dan Pengendalian Corona Virus deases (Covid-19). Kementrian Kesehat. 2020;5:178.

16.   Dhir SK, Verma D, Batta M, et al. E-learning in medical education in India. Indian Pediatr. 2017;54(10):871–7.

17.   European Society of cardiology. ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic. 2020;1–115.

18. Atri D, Siddiqi HK, Lang JP, et al. COVID-19 for the Cardiologist: Basic Virology, Epidemiology, Cardiac Manifestations, and Potential Therapeutic Strategies. JACC Basic to Transl Sci. 2020;5(5):518–36.

19. Gheblawi M, Wang K, Viveiros A, et al. Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. Circ Res. 2020;1456–74.

20. Fajgenbaum DC, June CH. Cytokine Storm. N Engl J Med. 2020;383(23):2255–73.

21. Bhaskar S, Sinha A, Banach M, et al. Cytokine Storm in COVID-19— Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper. Front Immunol. 2020;11(July).

22. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the 'Cytokine Storm'' in COVID-19.' J Infect. 2020;80(6):607–13.

23. Henderson LA, Canna SW, Schulert GS, et al. On the Alert for Cytokine Storm: Immunopathology in COVID-19. Arthritis Rheumatol. 2020;72(7):1059–63.

24. England JT, Abdulla A, Biggs CM, et al. Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes. Blood Rev. 2021;45(xxxx):100707.

25. Tang Y, Liu J, Zhang D, et al. Cytokine Storm in COVID-19: The Current

Evidence and Treatment Strategies. Front Immunol. 2020;11(July):1–13.

26. Kappert K, Jahić A, Tauber R. Assessment of serum ferritin as a biomarker in COVID-19: bystander or participant? Insights by comparison with other infectious and non-infectious diseases. Biomarkers. 2020;0(0):1–36.

27. Wang L. C-reactive protein levels in the early stage of COVID-19. Med Mal Infect. 2020;50(4):332–4.

28. Matsumoto H, Kasai T, Sato A, et al. Association between C-reactive protein levels at hospital admission and long-term mortality in patients with acute decompensated heart failure. Heart Vessels. 2019;34(12):1961–8.

29. Carubbi F, Salvati L, Alunno A, et al. Ferritin is associated with the severity of lung involvement but not with worse prognosis in patients with COVID-19: data from two Italian COVID-19 units. Sci Rep. 2021;11(1):1–11.

30. Rasyid H, Sangkereng A, Harjianti T, et al. Impact of age to ferritin and neutrophil-lymphocyte ratio as biomarkers for intensive care requirement and mortality risk in COVID-19 patients in Makassar, Indonesia. Physiol Rep. 2021;9(10):1–10.

31. Qu M, Zhang H, Chen Z, et al. The Role of Ferroptosis in Acute Respiratory Distress Syndrome. Front Med. 2021;8(May):1–8.

32. Zhou B, She J, Wang Y, et al. Utility of Ferritin, Procalcitonin, and C-reactive Protein in Severe Patients with 2019 Novel Coronavirus Disease. 2020;1–12.

33. Habib HM, Ibrahim S, Zaim A, et al. The role of iron in the pathogenesis of

COVID-19 and possible treatment with lactoferrin and other iron chelators. Biomed Pharmacother. 2021;136:111228.

34. Wu Z, McGoogan JM. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention. JAMA - J Am Med Assoc. 2020;323(13):1239–42.

35. Sun Y, Dong Y, Wang L, et al. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19 . The COVID-19 resource centre is hosted on Elsevier Connect , the company ' s public news and information . 2020;(January).